| BackgroundChina is an HBV-epidemic area. As reported by Chinese Healthy Ministry in2008,the rate of hepatitis B surface antigen carrier is7.18%in Chinese people aging from1-59years. Chronic HBV infection is characterized by persistent Hepatitis B surfaceantigen positive. The serum HBsAg level was correlated with the HBV DNAreplication. Therefore, serum HBsAg was considered to have predictable anddiagnosing importance in HBV-infected patients. In recent years, Fibroscan is alsowidely used for the assessment of liver condition in patients. The aim of this study wasto investigate the prognostic and diagnostic effects of HBsAg and Fibroscan in patientswith chronic HBV.This project consists of three parts:1elucidating the correlation between serumlevel of HBsAg and HBV DNA in HBV-infected patients with or without liver cirrhosis;2. Investigating the variations of HBsAg, HBV DNA and liver fibrosis degree in patientreceiving anti-viral treatment;3. The HBsAg and LSM in the clinical course ofanti-viral treatment with Peg-IFN.Study designPatients491patients were included in this study. A diagnosis of HBV infection was madeaccording to the twelfth National Viral Hepatitis Conference in2005. The excludingcriteria were thyroid diseases, autoimmune diseases, cancer and so on. Patients in thisstudy did not receive immunomodulatory therapy and (or) anti-viral treatment in3 month..Methods(1) Serum HBVDNA levels: fluorescence quantitative polymerase chain reaction(PCR),(2) Serum HBsAg levels: serum HBsAg was detected by the chemiluminescencemicroparticle immunoassay technology.(3) FibroScan test: the instantaneous elastic wave as the core technology, the shearelasticity probe transient elastography determination of the patient ’s liver.Results1. The correlation between HBsAg and HBV DNAlevels: In patients with e-antigenpositive, there was a positive correlation between HBsAg and HBV DNAexcept forpatients with liver cirrhosis. In patients with e-antigen negative, there was nosignificant difference among various degree of liver fibrosis, but the level of serumHBV DNAmarked increased in patients with compensated liver cirrhosis comparedwith patients with decompensated liver cirrhosis.2. Correlation analysis: patients in this study were divided into3groups: low HBsAg, medium HBsAg, high HBsAg group. There was significant difference in theHBV DNAlevel among three groups. In patients with HBsAg>10000, HBsAg washighly correlated with HBV DNAlevel. However, there was no significantdifference between HBsAg and LSM.3. LSM test: In patients with e antigen positive treated with Peg-IFN, LSM in patientswith complete viral response was lower than in patients with non-complete viralresponse. At12weeks and48weeks, HBsAg acted in consistent with LSM.Conclusions:1. Hepatitis B surface antigen serum level was correlated with HBV DNA, especially in patients with HBV e antigen positive. Serum HBsAg level reflected HBV DNAreplication.2. There was no significant difference between HBsAg and degree of liver fibrosis inHBV-infected patients.3. LSM had predictable importance in e-antigen positive patients treated with Peg-IFN. |
PDF Full Text Request